First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

(2010) David W. Miles et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study

(2010) Lucio Crinò et al.   LANCET ONCOLOGY

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study

(2009) E. Van Cutsem et al.   ANNALS OF ONCOLOGY

The function of vascular endothelial growth factor

(2009) Bonnie J. Nieves et al.   BIOFACTORS

Gastrosplenic Fistula From Hodgkin's Lymphoma

(2009) Carolyn D. Seib et al.   JOURNAL OF CLINICAL ONCOLOGY

Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer

(2009) Robert Gray et al.   JOURNAL OF CLINICAL ONCOLOGY

Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis

(2009) Sanjaykumar Hapani et al.   LANCET ONCOLOGY

Clinical Outcomes Associated with Bevacizumab-Containing Treatment of Metastatic Colorectal Cancer: The BRiTE Observational Cohort Study

(2009) M. Kozloff et al.   ONCOLOGIST

Gemcitabine Plus Paclitaxel Versus Paclitaxel Monotherapy in Patients With Metastatic Breast Cancer and Prior Anthracycline Treatment

(2008) Kathy S. Albain et al.   JOURNAL OF CLINICAL ONCOLOGY